**Supplementary Table S1*: Therapeutic candidate genes for lung cancer***

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene ID** | **Official Symbol** | **Full name** | **Alias** | **Location** | **Family/ Function** | **Ref.** |
| 3832 | KIF11 | kinesin family member 11 | Eg5; HKSP; KNSL1 | 10q24.1 | kinesin-like protein family/motor protein | (1, 2, 3) |
| 4101 | MAGE-A2 | melanoma antigen family A, 2 | CT1.2; MAGE2 | Xq28 | MAGEA gene family/p53 transcriptional suppression | (4) |
| 5347 | PLK1 | polo-like kinase 1 | PLK; STPK13 | 16p12.2 | Serine/threonine-protein kinase | (5, 6) |
| 9493 | KIF23 | kinesin family member 23 | CHO1, KNSL5, MKLP-1 | 15q23 | kinesin-like protein family/motor protein | (7) |
| 10403 | NDC80 | NDC80 kinetochore complex component | HEC; KNTC2 | 18p11.32  | organize and stabilize microtubule-kinetochore interactions and is required for proper chromosome segregation | (8) |
| 57082 | CASC5 | cancer susceptibility candidate 5 | D40; CT29; AF15Q14 | 15q14 | a component of the multiprotein assembly that is required for creation of kinetochore-microtubule attachments and chromosome segregation. | (9) |
| 83450 | NUF2 | NUF2, NDC80 kinetochore complex component | CDCA1; CT106 | 1q23.3 | a component of a conserved protein complex associated with the centromere  | (8) |
| 113130 | CDCA5 | cell division cycle associated 5 | SORORIN | 11q12.1 | Regulator of sister chromatid cohesion in mitosis | (10) |

([1-6](#_ENREF_1)) ([7](#_ENREF_7)) ([8](#_ENREF_8)) ([9](#_ENREF_9)) ([10](#_ENREF_10))

References:

1. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer discovery. 2013;3:406-17.

2. Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K, et al. Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer. 2006;54:217-25.

3. Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ, et al. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19:1994-2003.

4. Bhan S, Negi SS, Shao C, Glazer CA, Chuang A, Gaykalova DA, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17:4267-76.

5. McCarroll JA, Dwarte T, Baigude H, Dang J, Yang L, Erlich RB, et al. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer. Oncotarget. 2014.

6. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. Journal of the National Cancer Institute. 2004;96:862-72.

7. Kato T, Wada H, Patel P, Hu HP, Lee D, Ujiie H, et al. Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients. Lung Cancer. 2016;92:53-61.

8. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer research. 2006;66:10339-48.

9. Takimoto M, Wei G, Dosaka-Akita H, Mao P, Kondo S, Sakuragi N, et al. Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers. British journal of cancer. 2002;86:1757-62.

10. Nguyen MH, Koinuma J, Ueda K, Ito T, Tsuchiya E, Nakamura Y, et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer research. 2010;70:5337-47.